MB ChB DPhil FRCOphth FRCS
Professor of Ophthalmology
- Professor of Ophthalmology, University of Oxford
- Consultant Vitreoretinal Surgeon
- Fellow of Merton College
Our clinical and laboratory research is dedicated to finding new treatments for blindness, particularly in patients with incurable retinal diseases, using stem cell-based approaches, gene therapy or electronic retinas. We are also developing new techniques for cataract and retinal surgery. Our recent key research achievements include:
2014: First results in gene therapy clinical trial for choroideremia have now been published in The Lancet (see abstract).
- 2013: First reconstruction of the outer retina using a cell therapy approach in mice that are completely blind from end-stage retinal degeneration - overcoming one of the last hurdles for developing stem cell treatments for blind patients (Singh et al., PNAS; 2013).
- 2012: First electronic retinal implant surgery in the UK as part of a multicentre clinical trial with Retina Implant AG. Six patients have now been recruited for retinal implant surgery in Oxford and will be followed up for one year.
Robert MacLaren is Professor of Ophthalmology at the University of Oxford, Consultant Ophthalmologist at the Oxford Eye Hospital, Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology, Honorary Consultant Vitreoretinal Surgeon at Moorfields Eye Hospital, Honorary Consultant Ophthalmologist at Great Ormond Street Children's Hospital, Faculty Member and Founding Theme Leader of the Moorfields-UCL Institute of Ophthalmology Biomedical Research Centre. He is also a Fellow of the Royal College of Ophthalmologists, Fellow and former King James IV Professor of Surgery at the Royal College of Surgeons of Edinburgh, Fellow of the Higher Education Academy and Bodley Fellow of Merton College Oxford. In 2013 he was a recipient of the international ARVO Camras Award.
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.
MacLaren RE. et al, (2014), Lancet, 383, 1129 - 1137
Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation.
Singh MS. et al, (2013), Proc Natl Acad Sci U S A, 110, 1101 - 1106
Assessment of 180° rotation of the choroid as a novel surgical treatment for age-related macular degeneration.
Lee E. et al, (2012), Invest Ophthalmol Vis Sci, 53, 2523 - 2532
Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration.
MacLaren RE. et al, (2007), Ophthalmology, 114, 561 - 570
Retinal repair by transplantation of photoreceptor precursors.
MacLaren RE. et al, (2006), Nature, 444, 203 - 207
Functional Defects in Color Vision in Patients With Choroideremia.
Jolly JK. et al, (2015), Am J Ophthalmol, 160, 822 - 831.e3
Isoforms of Melanopsin Mediate Different Behavioral Responses to Light.
Jagannath A. et al, (2015), Curr Biol, 25, 2430 - 2434
Gene Therapy for Retinal Disease: What Lies Ahead.
MacLaren RE., (2015), Ophthalmologica, 234, 1 - 5
CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa.
Lipinski DM. et al, (2015), Mol Ther, 23, 1308 - 1319
Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization.
Charbel Issa P. et al, (2015), Proc Natl Acad Sci U S A, 112, 8415 - 8420
Sources of Funding
- The Health Foundation
- The Medical Research Council UK
- The Royal Blind
- The Scottish Council on Visual Impairment
- The Royal College of Surgeons of Edinburgh
- The Special Trustees of Moorfields Eye Hospital
- The Wellcome Trust
- Fight for Sight
- The Lanvern Foundation
- The Oxford Stem Cell Institute
- The National Institute for Health Research